Conduit Financial Statements From 2010 to 2025

CDT Stock   1.29  0.02  1.53%   
Analyzing historical trends in various income statement and balance sheet accounts from Conduit Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Conduit Pharmaceuticals' valuation are summarized below:
Market Capitalization
1.9 M
Earnings Share
(179.34)
There are currently ninety fundamental signals for Conduit Pharmaceuticals that can be evaluated and compared over time across rivals. All traders should validate Conduit Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 567.2 K, Selling General Administrative of 6.4 M or Total Revenue of 968.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Conduit Stock
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Conduit Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.2 M4.2 M1.1 M
Slightly volatile
Short and Long Term Debt Total7.8 M7.5 M1.3 M
Slightly volatile
Other Current Liabilities1.7 MM505.1 K
Slightly volatile
Total Current Liabilities11.3 M10.7 M1.9 M
Slightly volatile
Other Liabilities3.9 M4.7 M3.3 M
Slightly volatile
Cash526.3 K554 K389.8 K
Slightly volatile
Non Current Assets Total847.8 K1.5 M320.6 K
Slightly volatile
Long Term Debt1.5 M2.3 M1.1 M
Slightly volatile
Cash And Short Term Investments526.3 K554 K389.8 K
Slightly volatile
Common Stock Shares OutstandingK7.2 K1.3 K
Slightly volatile
Liabilities And Stockholders Equity3.2 M4.2 M1.1 M
Slightly volatile
Non Current Liabilities Total232.8 K245 K3.5 M
Pretty Stable
Other Current Assets971.7 K1.7 M319.8 K
Slightly volatile
Total LiabilitiesM11 M2.4 M
Slightly volatile
Total Current Assets2.5 M2.7 M804.6 K
Slightly volatile
Short Term Debt7.7 M7.3 M1.1 M
Slightly volatile
Common Stock7.5 K14 K2.4 K
Slightly volatile
Deferred Long Term LiabilitiesK4.5 K4.9 K
Slightly volatile
Short and Long Term Debt7.6 M7.2 M1.1 M
Slightly volatile
Intangible Assets506 M481.9 M87.9 M
Slightly volatile
Net Receivables391.2 K440.1 K479.8 K
Slightly volatile
Good Will814.9 M916.8 M999.6 M
Slightly volatile
Short Term Investments295.8 M332.8 M362.8 M
Slightly volatile
Inventory274.5 M308.8 M336.7 M
Slightly volatile

Conduit Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization567.2 K457 K545.4 K
Pretty Stable
Selling General Administrative6.4 M12 M3.8 M
Slightly volatile
Other Operating Expenses16.2 M15.4 M4.9 M
Slightly volatile
Research Development3.5 M3.4 M657.6 K
Slightly volatile
Total Operating Expenses15.7 M15 M4.8 M
Slightly volatile
Cost Of Revenue365.6 K411.3 K448.4 K
Slightly volatile

Conduit Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings1.8 M2.5 M993.4 K
Slightly volatile
Begin Period Cash Flow4.4 M4.2 M755.4 K
Slightly volatile
Change To Operating Activities781.2 K536.4 K1.2 M
Slightly volatile
Total Cash From Financing Activities5.9 M6.1 MM
Slightly volatile
End Period Cash Flow526.3 K554 K389.8 K
Slightly volatile
Change To Netincome1.2 M2.3 M585.2 K
Slightly volatile
Change To Inventory19.5 M21.9 M23.9 M
Slightly volatile
Dividends Paid6.6 M7.4 MM
Slightly volatile
Change To Account Receivables15.1 M17 M18.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.0880.10.1094
Slightly volatile
Payables Turnover0.260.290.3144
Slightly volatile
Cash Per Share0.260.272363.5551
Slightly volatile
Days Payables Outstanding912K1.1 K
Slightly volatile
Income Quality0.520.54391.4391
Slightly volatile
Intangibles To Total Assets274309336
Slightly volatile
Current Ratio0.240.25280.8345
Slightly volatile
Capex Per Share0.02010.02260.0246
Slightly volatile
Interest Debt Per Share4.184.4051231
Slightly volatile
Debt To Assets1.871.77840.8681
Pretty Stable
Days Of Payables Outstanding912K1.1 K
Slightly volatile
Quick Ratio0.240.25280.8345
Slightly volatile
Cash Ratio0.0490.05160.4889
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9865
Slightly volatile
Debt Ratio1.871.77840.8681
Pretty Stable

Conduit Fundamental Market Drivers

Conduit Upcoming Events

19th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Conduit Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Conduit Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Conduit Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue922.2 M968.3 M
Cost Of Revenue411.3 K365.6 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.